1. New strategy of drug repositioning through anti‐fibrosis characteristic
- Author
-
Na Jiao, Dingfeng Wu, Meifei Yuan, Lixin Zhu, Xiaoyi Li, Zi-Huan Yang, and Ruixin Zhu
- Subjects
Drug ,business.industry ,media_common.quotation_subject ,Computational biology ,medicine.disease ,Biochemistry ,Anti fibrosis ,Drug repositioning ,Fibrosis ,Genetics ,medicine ,business ,Molecular Biology ,DrugBank ,Biotechnology ,media_common - Abstract
Background Fibrosis is a common pathogenesis in most diseases, thus different diseases may share targets and drugs related to fibrosis. For a drug that targets fibrotic process, it is likely an effective drug for treating diseases other than its original purpose. Therefore, the current study aimed to investigate the anti-fibrosis characteristic of drugs for repositioning purpose. Method Anti-fibrosis compounds identified from PubMed and ClinicalTrials.gov were selected as positive samples. FDA-approved drugs from DrugBank and compounds from Connectivity Map (CMap) were selected as potential negative samples after excluding those compounds known as anti-fibrosis drugs. MACCS Keys fingerprint (RDKit) and molecule-stimulated gene signatures (CMap) are collected as the structural descriptors and transcriptomic profiles of compounds respectively. OneClassSVM was used to remove outliers. Gradient Boosting Classifier was performed to build a Structural Model based on molecular structures and to build a Gene Mode...
- Published
- 2019
- Full Text
- View/download PDF